Last week, the Department of Health and Human Services (HHS) recommended rescheduling cannabis from schedule I to III under the Controlled Substances Act (CSA). My colleagues already covered various implications of the proposed cannabis rescheduling (see here and here). Today, I want to talk about one of the most important consequences of the announcement other than

The post What Rescheduling Means for Cannabis Investments appeared first on Harris Bricken Sliwoski LLP.

Cannabis Brands and China Challenges Cannabis brands account for a sizeable component of my law firm’s intellectual property work (and, indeed, our work generally). Historically, there has been little overlap between our cannabis and China practice areas, beyond our representing a number of cannabis ancillary product companies on their China manufacturing matters. This is starting to change,

The post Cannabis Brands and China: An Emerging IP Challenge appeared first on Harris Bricken Sliwoski LLP.